Pharma & Healthcare
Global Chronic Hepatitis B Oral Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 608286
- Pages: 161
- Figures: 152
- Views: 23
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Chronic Hepatitis B Oral Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Chronic Hepatitis B Oral Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Chronic Hepatitis B Oral Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Chronic Hepatitis B Oral Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Chronic Hepatitis B Oral Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Chronic Hepatitis B Oral Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Market Segmentation by Application
1.3.1 Global Chronic Hepatitis B Oral Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Chronic Hepatitis B Oral Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Chronic Hepatitis B Oral Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Chronic Hepatitis B Oral Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Chronic Hepatitis B Oral Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Chronic Hepatitis B Oral Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Chronic Hepatitis B Oral Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Entecavir Market Size by Manufacturers
3.5.2 Tenofovir Market Size by Manufacturers
3.5.3 Lamivudine Market Size by Manufacturers
3.5.4 Adefovir Market Size by Manufacturers
3.5.5 Telbivudine Market Size by Manufacturers
3.5.6 Others Market Size by Manufacturers
3.6 Global Chronic Hepatitis B Oral Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Chronic Hepatitis B Oral Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Chronic Hepatitis B Oral Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Chronic Hepatitis B Oral Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Chronic Hepatitis B Oral Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Chronic Hepatitis B Oral Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Chronic Hepatitis B Oral Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Chronic Hepatitis B Oral Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Chronic Hepatitis B Oral Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Chronic Hepatitis B Oral Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.1.4 GSK Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 GSK Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.1.6 GSK Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.1.7 GSK Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.1.8 GSK Chronic Hepatitis B Oral Drugs SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Corporation Information
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.2.4 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.2.6 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.2.7 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.2.8 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs SWOT Analysis
11.2.9 Bristol Myers Squibb Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.3.4 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.3.6 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.3.7 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.3.8 Gilead Sciences Chronic Hepatitis B Oral Drugs SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.4.4 Novartis Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.4.6 Novartis Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.4.7 Novartis Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.4.8 Novartis Chronic Hepatitis B Oral Drugs SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.5.4 Roche Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Roche Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.5.6 Roche Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.5.7 Roche Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.5.8 Roche Chronic Hepatitis B Oral Drugs SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Merck
11.6.1 Merck Corporation Information
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.6.4 Merck Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Merck Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.7.4 Johnson & Johnson Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Johnson & Johnson Recent Developments
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Corporation Information
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.8.4 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Dawnrays Pharmaceutical Recent Developments
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Corporation Information
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.9.4 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Hansoh Pharmaceutical Recent Developments
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Corporation Information
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.10.4 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Corporation Information
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.11.4 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Qilu pharmaceutical Recent Developments
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Corporation Information
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.12.4 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Fujian Cosunter Pharma Recent Developments
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Corporation Information
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.13.4 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Xiamen Amoytop Biotech Recent Developments
11.14 YaoPharma
11.14.1 YaoPharma Corporation Information
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.14.4 YaoPharma Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 YaoPharma Recent Developments
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Corporation Information
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.15.4 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Kelun Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Chronic Hepatitis B Oral Drugs Industry Chain
12.2 Chronic Hepatitis B Oral Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Chronic Hepatitis B Oral Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Chronic Hepatitis B Oral Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Chronic Hepatitis B Oral Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Chronic Hepatitis B Oral Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Chronic Hepatitis B Oral Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Chronic Hepatitis B Oral Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Market Segmentation by Application
1.3.1 Global Chronic Hepatitis B Oral Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Chronic Hepatitis B Oral Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Chronic Hepatitis B Oral Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Chronic Hepatitis B Oral Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Chronic Hepatitis B Oral Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Chronic Hepatitis B Oral Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Chronic Hepatitis B Oral Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Entecavir Market Size by Manufacturers
3.5.2 Tenofovir Market Size by Manufacturers
3.5.3 Lamivudine Market Size by Manufacturers
3.5.4 Adefovir Market Size by Manufacturers
3.5.5 Telbivudine Market Size by Manufacturers
3.5.6 Others Market Size by Manufacturers
3.6 Global Chronic Hepatitis B Oral Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Chronic Hepatitis B Oral Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Chronic Hepatitis B Oral Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Chronic Hepatitis B Oral Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Chronic Hepatitis B Oral Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Chronic Hepatitis B Oral Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Chronic Hepatitis B Oral Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Chronic Hepatitis B Oral Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Chronic Hepatitis B Oral Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Chronic Hepatitis B Oral Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Chronic Hepatitis B Oral Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Chronic Hepatitis B Oral Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.1.4 GSK Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 GSK Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.1.6 GSK Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.1.7 GSK Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.1.8 GSK Chronic Hepatitis B Oral Drugs SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Corporation Information
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.2.4 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.2.6 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.2.7 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.2.8 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs SWOT Analysis
11.2.9 Bristol Myers Squibb Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.3.4 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.3.6 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.3.7 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.3.8 Gilead Sciences Chronic Hepatitis B Oral Drugs SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.4.4 Novartis Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.4.6 Novartis Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.4.7 Novartis Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.4.8 Novartis Chronic Hepatitis B Oral Drugs SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.5.4 Roche Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Roche Chronic Hepatitis B Oral Drugs Sales by Product in 2024
11.5.6 Roche Chronic Hepatitis B Oral Drugs Sales by Application in 2024
11.5.7 Roche Chronic Hepatitis B Oral Drugs Sales by Geographic Area in 2024
11.5.8 Roche Chronic Hepatitis B Oral Drugs SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Merck
11.6.1 Merck Corporation Information
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.6.4 Merck Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Merck Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.7.4 Johnson & Johnson Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Johnson & Johnson Recent Developments
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Corporation Information
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.8.4 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Dawnrays Pharmaceutical Recent Developments
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Corporation Information
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.9.4 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Hansoh Pharmaceutical Recent Developments
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Corporation Information
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.10.4 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Corporation Information
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.11.4 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Qilu pharmaceutical Recent Developments
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Corporation Information
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.12.4 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Fujian Cosunter Pharma Recent Developments
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Corporation Information
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.13.4 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Xiamen Amoytop Biotech Recent Developments
11.14 YaoPharma
11.14.1 YaoPharma Corporation Information
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.14.4 YaoPharma Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 YaoPharma Recent Developments
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Corporation Information
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Product Models, Descriptions and Specifications
11.15.4 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Kelun Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Chronic Hepatitis B Oral Drugs Industry Chain
12.2 Chronic Hepatitis B Oral Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Chronic Hepatitis B Oral Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Chronic Hepatitis B Oral Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Chronic Hepatitis B Oral Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Chronic Hepatitis B Oral Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Chronic Hepatitis B Oral Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Chronic Hepatitis B Oral Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Chronic Hepatitis B Oral Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Chronic Hepatitis B Oral Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Chronic Hepatitis B Oral Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Chronic Hepatitis B Oral Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Chronic Hepatitis B Oral Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Chronic Hepatitis B Oral Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Chronic Hepatitis B Oral Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Hepatitis B Oral Drugs as of 2024)
Table 16. Global Chronic Hepatitis B Oral Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Chronic Hepatitis B Oral Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Chronic Hepatitis B Oral Drugs Manufacturing Base and Headquarters
Table 19. Global Chronic Hepatitis B Oral Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Chronic Hepatitis B Oral Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Chronic Hepatitis B Oral Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Chronic Hepatitis B Oral Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Chronic Hepatitis B Oral Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Chronic Hepatitis B Oral Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Chronic Hepatitis B Oral Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Chronic Hepatitis B Oral Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Chronic Hepatitis B Oral Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Chronic Hepatitis B Oral Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Chronic Hepatitis B Oral Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Chronic Hepatitis B Oral Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Chronic Hepatitis B Oral Drugs Growth Accelerators and Market Barriers
Table 37. North America Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Chronic Hepatitis B Oral Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Chronic Hepatitis B Oral Drugs Growth Accelerators and Market Barriers
Table 40. Europe Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Chronic Hepatitis B Oral Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Chronic Hepatitis B Oral Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Chronic Hepatitis B Oral Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Chronic Hepatitis B Oral Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. GSK Corporation Information
Table 51. GSK Description and Major Businesses
Table 52. GSK Product Models, Descriptions and Specifications
Table 53. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. GSK Sales Value Proportion by Product in 2024
Table 55. GSK Sales Value Proportion by Application in 2024
Table 56. GSK Sales Value Proportion by Geographic Area in 2024
Table 57. GSK Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 58. GSK Recent Developments
Table 59. Bristol Myers Squibb Corporation Information
Table 60. Bristol Myers Squibb Description and Major Businesses
Table 61. Bristol Myers Squibb Product Models, Descriptions and Specifications
Table 62. Bristol Myers Squibb Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Bristol Myers Squibb Sales Value Proportion by Product in 2024
Table 64. Bristol Myers Squibb Sales Value Proportion by Application in 2024
Table 65. Bristol Myers Squibb Sales Value Proportion by Geographic Area in 2024
Table 66. Bristol Myers Squibb Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 67. Bristol Myers Squibb Recent Developments
Table 68. Gilead Sciences Corporation Information
Table 69. Gilead Sciences Description and Major Businesses
Table 70. Gilead Sciences Product Models, Descriptions and Specifications
Table 71. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Gilead Sciences Sales Value Proportion by Product in 2024
Table 73. Gilead Sciences Sales Value Proportion by Application in 2024
Table 74. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 75. Gilead Sciences Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 76. Gilead Sciences Recent Developments
Table 77. Novartis Corporation Information
Table 78. Novartis Description and Major Businesses
Table 79. Novartis Product Models, Descriptions and Specifications
Table 80. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Novartis Sales Value Proportion by Product in 2024
Table 82. Novartis Sales Value Proportion by Application in 2024
Table 83. Novartis Sales Value Proportion by Geographic Area in 2024
Table 84. Novartis Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 85. Novartis Recent Developments
Table 86. Roche Corporation Information
Table 87. Roche Description and Major Businesses
Table 88. Roche Product Models, Descriptions and Specifications
Table 89. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Roche Sales Value Proportion by Product in 2024
Table 91. Roche Sales Value Proportion by Application in 2024
Table 92. Roche Sales Value Proportion by Geographic Area in 2024
Table 93. Roche Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 94. Roche Recent Developments
Table 95. Merck Corporation Information
Table 96. Merck Description and Major Businesses
Table 97. Merck Product Models, Descriptions and Specifications
Table 98. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Merck Recent Developments
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Major Businesses
Table 102. Johnson & Johnson Product Models, Descriptions and Specifications
Table 103. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Johnson & Johnson Recent Developments
Table 105. Dawnrays Pharmaceutical Corporation Information
Table 106. Dawnrays Pharmaceutical Description and Major Businesses
Table 107. Dawnrays Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Dawnrays Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Dawnrays Pharmaceutical Recent Developments
Table 110. Hansoh Pharmaceutical Corporation Information
Table 111. Hansoh Pharmaceutical Description and Major Businesses
Table 112. Hansoh Pharmaceutical Product Models, Descriptions and Specifications
Table 113. Hansoh Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Hansoh Pharmaceutical Recent Developments
Table 115. Chia Tai-Tianqing Pharmaceutical Corporation Information
Table 116. Chia Tai-Tianqing Pharmaceutical Description and Major Businesses
Table 117. Chia Tai-Tianqing Pharmaceutical Product Models, Descriptions and Specifications
Table 118. Chia Tai-Tianqing Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Chia Tai-Tianqing Pharmaceutical Recent Developments
Table 120. Qilu pharmaceutical Corporation Information
Table 121. Qilu pharmaceutical Description and Major Businesses
Table 122. Qilu pharmaceutical Product Models, Descriptions and Specifications
Table 123. Qilu pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Qilu pharmaceutical Recent Developments
Table 125. Fujian Cosunter Pharma Corporation Information
Table 126. Fujian Cosunter Pharma Description and Major Businesses
Table 127. Fujian Cosunter Pharma Product Models, Descriptions and Specifications
Table 128. Fujian Cosunter Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Fujian Cosunter Pharma Recent Developments
Table 130. Xiamen Amoytop Biotech Corporation Information
Table 131. Xiamen Amoytop Biotech Description and Major Businesses
Table 132. Xiamen Amoytop Biotech Product Models, Descriptions and Specifications
Table 133. Xiamen Amoytop Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Xiamen Amoytop Biotech Recent Developments
Table 135. YaoPharma Corporation Information
Table 136. YaoPharma Description and Major Businesses
Table 137. YaoPharma Product Models, Descriptions and Specifications
Table 138. YaoPharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. YaoPharma Recent Developments
Table 140. Kelun Pharmaceutical Corporation Information
Table 141. Kelun Pharmaceutical Description and Major Businesses
Table 142. Kelun Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Kelun Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Kelun Pharmaceutical Recent Developments
Table 145. Key Raw Materials Distribution
Table 146. Raw Materials Key Suppliers
Table 147. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 148. Milestones in Production Technology Evolution
Table 149. Distributors List
Table 150. Market Trends and Market Evolution
Table 151. Market Drivers and Opportunities
Table 152. Market Challenges, Risks, and Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Chronic Hepatitis B Oral Drugs Product Picture
Figure 2. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Entecavir Product Picture
Figure 4. Tenofovir Product Picture
Figure 5. Lamivudine Product Picture
Figure 6. Adefovir Product Picture
Figure 7. Telbivudine Product Picture
Figure 8. Others Product Picture
Figure 9. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Chronic Hepatitis B Oral Drugs Report Years Considered
Figure 14. Global Chronic Hepatitis B Oral Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 16. Global Chronic Hepatitis B Oral Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Region (2020-2031)
Figure 18. Global Chronic Hepatitis B Oral Drugs Sales (2020-2031) & (K Units)
Figure 19. Global Chronic Hepatitis B Oral Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Chronic Hepatitis B Oral Drugs Sales Volume Market Share in 2024
Figure 22. Global Chronic Hepatitis B Oral Drugs Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Entecavir Revenue Market Share by Manufacturer in 2024
Figure 25. Tenofovir Revenue Market Share by Manufacturer in 2024
Figure 26. Lamivudine Revenue Market Share by Manufacturer in 2024
Figure 27. Adefovir Revenue Market Share by Manufacturer in 2024
Figure 28. Telbivudine Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2020-2031)
Figure 31. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2020-2031)
Figure 32. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2020-2031)
Figure 33. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application (2020-2031)
Figure 34. North America Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 35. North America Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 37. North America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 47. Europe Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. France Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 67. India Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 88. Chronic Hepatitis B Oral Drugs Industry Chain Mapping
Figure 89. Regional Chronic Hepatitis B Oral Drugs Manufacturing Base Distribution (%)
Figure 90. Global Chronic Hepatitis B Oral Drugs Production Market Share by Region (2020-2031)
Figure 91. Chronic Hepatitis B Oral Drugs Production Process
Figure 92. Regional Chronic Hepatitis B Oral Drugs Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Table 1. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Chronic Hepatitis B Oral Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Chronic Hepatitis B Oral Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Chronic Hepatitis B Oral Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Chronic Hepatitis B Oral Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Chronic Hepatitis B Oral Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Chronic Hepatitis B Oral Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Chronic Hepatitis B Oral Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Chronic Hepatitis B Oral Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Chronic Hepatitis B Oral Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Hepatitis B Oral Drugs as of 2024)
Table 16. Global Chronic Hepatitis B Oral Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Chronic Hepatitis B Oral Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Chronic Hepatitis B Oral Drugs Manufacturing Base and Headquarters
Table 19. Global Chronic Hepatitis B Oral Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Chronic Hepatitis B Oral Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Chronic Hepatitis B Oral Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Chronic Hepatitis B Oral Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Chronic Hepatitis B Oral Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Chronic Hepatitis B Oral Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Chronic Hepatitis B Oral Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Chronic Hepatitis B Oral Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Chronic Hepatitis B Oral Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Chronic Hepatitis B Oral Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Chronic Hepatitis B Oral Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Chronic Hepatitis B Oral Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Chronic Hepatitis B Oral Drugs Growth Accelerators and Market Barriers
Table 37. North America Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Chronic Hepatitis B Oral Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Chronic Hepatitis B Oral Drugs Growth Accelerators and Market Barriers
Table 40. Europe Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Chronic Hepatitis B Oral Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Chronic Hepatitis B Oral Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Chronic Hepatitis B Oral Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Chronic Hepatitis B Oral Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Chronic Hepatitis B Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. GSK Corporation Information
Table 51. GSK Description and Major Businesses
Table 52. GSK Product Models, Descriptions and Specifications
Table 53. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. GSK Sales Value Proportion by Product in 2024
Table 55. GSK Sales Value Proportion by Application in 2024
Table 56. GSK Sales Value Proportion by Geographic Area in 2024
Table 57. GSK Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 58. GSK Recent Developments
Table 59. Bristol Myers Squibb Corporation Information
Table 60. Bristol Myers Squibb Description and Major Businesses
Table 61. Bristol Myers Squibb Product Models, Descriptions and Specifications
Table 62. Bristol Myers Squibb Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Bristol Myers Squibb Sales Value Proportion by Product in 2024
Table 64. Bristol Myers Squibb Sales Value Proportion by Application in 2024
Table 65. Bristol Myers Squibb Sales Value Proportion by Geographic Area in 2024
Table 66. Bristol Myers Squibb Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 67. Bristol Myers Squibb Recent Developments
Table 68. Gilead Sciences Corporation Information
Table 69. Gilead Sciences Description and Major Businesses
Table 70. Gilead Sciences Product Models, Descriptions and Specifications
Table 71. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Gilead Sciences Sales Value Proportion by Product in 2024
Table 73. Gilead Sciences Sales Value Proportion by Application in 2024
Table 74. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 75. Gilead Sciences Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 76. Gilead Sciences Recent Developments
Table 77. Novartis Corporation Information
Table 78. Novartis Description and Major Businesses
Table 79. Novartis Product Models, Descriptions and Specifications
Table 80. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Novartis Sales Value Proportion by Product in 2024
Table 82. Novartis Sales Value Proportion by Application in 2024
Table 83. Novartis Sales Value Proportion by Geographic Area in 2024
Table 84. Novartis Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 85. Novartis Recent Developments
Table 86. Roche Corporation Information
Table 87. Roche Description and Major Businesses
Table 88. Roche Product Models, Descriptions and Specifications
Table 89. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Roche Sales Value Proportion by Product in 2024
Table 91. Roche Sales Value Proportion by Application in 2024
Table 92. Roche Sales Value Proportion by Geographic Area in 2024
Table 93. Roche Chronic Hepatitis B Oral Drugs SWOT Analysis
Table 94. Roche Recent Developments
Table 95. Merck Corporation Information
Table 96. Merck Description and Major Businesses
Table 97. Merck Product Models, Descriptions and Specifications
Table 98. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Merck Recent Developments
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Major Businesses
Table 102. Johnson & Johnson Product Models, Descriptions and Specifications
Table 103. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Johnson & Johnson Recent Developments
Table 105. Dawnrays Pharmaceutical Corporation Information
Table 106. Dawnrays Pharmaceutical Description and Major Businesses
Table 107. Dawnrays Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Dawnrays Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Dawnrays Pharmaceutical Recent Developments
Table 110. Hansoh Pharmaceutical Corporation Information
Table 111. Hansoh Pharmaceutical Description and Major Businesses
Table 112. Hansoh Pharmaceutical Product Models, Descriptions and Specifications
Table 113. Hansoh Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Hansoh Pharmaceutical Recent Developments
Table 115. Chia Tai-Tianqing Pharmaceutical Corporation Information
Table 116. Chia Tai-Tianqing Pharmaceutical Description and Major Businesses
Table 117. Chia Tai-Tianqing Pharmaceutical Product Models, Descriptions and Specifications
Table 118. Chia Tai-Tianqing Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Chia Tai-Tianqing Pharmaceutical Recent Developments
Table 120. Qilu pharmaceutical Corporation Information
Table 121. Qilu pharmaceutical Description and Major Businesses
Table 122. Qilu pharmaceutical Product Models, Descriptions and Specifications
Table 123. Qilu pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Qilu pharmaceutical Recent Developments
Table 125. Fujian Cosunter Pharma Corporation Information
Table 126. Fujian Cosunter Pharma Description and Major Businesses
Table 127. Fujian Cosunter Pharma Product Models, Descriptions and Specifications
Table 128. Fujian Cosunter Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Fujian Cosunter Pharma Recent Developments
Table 130. Xiamen Amoytop Biotech Corporation Information
Table 131. Xiamen Amoytop Biotech Description and Major Businesses
Table 132. Xiamen Amoytop Biotech Product Models, Descriptions and Specifications
Table 133. Xiamen Amoytop Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Xiamen Amoytop Biotech Recent Developments
Table 135. YaoPharma Corporation Information
Table 136. YaoPharma Description and Major Businesses
Table 137. YaoPharma Product Models, Descriptions and Specifications
Table 138. YaoPharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. YaoPharma Recent Developments
Table 140. Kelun Pharmaceutical Corporation Information
Table 141. Kelun Pharmaceutical Description and Major Businesses
Table 142. Kelun Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Kelun Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Kelun Pharmaceutical Recent Developments
Table 145. Key Raw Materials Distribution
Table 146. Raw Materials Key Suppliers
Table 147. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 148. Milestones in Production Technology Evolution
Table 149. Distributors List
Table 150. Market Trends and Market Evolution
Table 151. Market Drivers and Opportunities
Table 152. Market Challenges, Risks, and Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Chronic Hepatitis B Oral Drugs Product Picture
Figure 2. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Entecavir Product Picture
Figure 4. Tenofovir Product Picture
Figure 5. Lamivudine Product Picture
Figure 6. Adefovir Product Picture
Figure 7. Telbivudine Product Picture
Figure 8. Others Product Picture
Figure 9. Global Chronic Hepatitis B Oral Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Chronic Hepatitis B Oral Drugs Report Years Considered
Figure 14. Global Chronic Hepatitis B Oral Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 16. Global Chronic Hepatitis B Oral Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Region (2020-2031)
Figure 18. Global Chronic Hepatitis B Oral Drugs Sales (2020-2031) & (K Units)
Figure 19. Global Chronic Hepatitis B Oral Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Chronic Hepatitis B Oral Drugs Sales Volume Market Share in 2024
Figure 22. Global Chronic Hepatitis B Oral Drugs Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Entecavir Revenue Market Share by Manufacturer in 2024
Figure 25. Tenofovir Revenue Market Share by Manufacturer in 2024
Figure 26. Lamivudine Revenue Market Share by Manufacturer in 2024
Figure 27. Adefovir Revenue Market Share by Manufacturer in 2024
Figure 28. Telbivudine Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2020-2031)
Figure 31. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2020-2031)
Figure 32. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2020-2031)
Figure 33. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application (2020-2031)
Figure 34. North America Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 35. North America Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 37. North America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 47. Europe Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. France Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 67. India Chronic Hepatitis B Oral Drugs Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Chronic Hepatitis B Oral Drugs Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Chronic Hepatitis B Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Chronic Hepatitis B Oral Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Chronic Hepatitis B Oral Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Chronic Hepatitis B Oral Drugs Revenue (2020-2025) & (US$ Million)
Figure 88. Chronic Hepatitis B Oral Drugs Industry Chain Mapping
Figure 89. Regional Chronic Hepatitis B Oral Drugs Manufacturing Base Distribution (%)
Figure 90. Global Chronic Hepatitis B Oral Drugs Production Market Share by Region (2020-2031)
Figure 91. Chronic Hepatitis B Oral Drugs Production Process
Figure 92. Regional Chronic Hepatitis B Oral Drugs Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232